Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Juan Francisco Vázquez-Costa. (2023) Do we really need to calculate a minimal important difference for ALSFRS-R?: A letter in response to ‘Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R’ published in Vol. 24(3–4), pp. 311–316. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 0:0, pages 1-2.
Read now
Read now
Bello Hamidou, Benoit Marin, Geraldine Lautrette, Marie Nicol, William Camu, Philippe Corcia, Marie-Christine Arnes-Bes, Christine Tranchant, Pierre Clavelou, Didier Hannequin, Giroud Maurice, Katell Beauvais, Jean-Christophe Antoine, Véronique Danel-Brunaud, Fausto Viader, Pierre-Marie Preux & Philippe Couratier. (2017) Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:7-8, pages 519-527.
Read now
Read now
Noah Lechtzin, Nicholas J. Maragakis, Richard Kimball, Anne Busse, Virginia Hoffman & Lora Clawson. (2009) Accurate ALSFRS-R scores can be generated from retrospective review of clinic notes. Amyotrophic Lateral Sclerosis 10:4, pages 244-247.
Read now
Read now
Petra Kaufmann, Gilbero Levy, Jacquelina Montes, Richaro Buchsbaum, Alexandra I. Barsdorf, Vanessa Battista, Rachel Arbing, Paul H. Gordon, Hiroshi Mitsumoto, Brvce Levin, John L. P. Thompson, Petra Kaufmann, Gilbero Levy, Jacquelina Montes, Richaro Buchsbaum, Alexandra I. Barsdorf, Vanessa Battista, Rachel Arbing, Paul H. Gordon, Hiroshi Mitsumoto, Brvce Levin & John L. P. Thompson. (2007) Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial. Amyotrophic Lateral Sclerosis 8:1, pages 42-46.
Read now
Read now
Articles from other publishers (7)
Sanjana Shellikeri, Reeman Marzouqah, Benjamin Rix Brooks, Lorne Zinman, Jordan R. Green & Yana Yunusova. (2021) Psychometric Properties of Rapid Word-Based Rate Measures in the Assessment of Bulbar Amyotrophic Lateral Sclerosis: Comparisons With Syllable-Based Rate Tasks. Journal of Speech, Language, and Hearing Research 64:11, pages 4178-4191.
Crossref
Crossref
Irene Zubiri, Vittoria Lombardi, Michael Bremang, Vikram Mitra, Giovanni Nardo, Rocco Adiutori, Ching-Hua Lu, Emanuela Leoni, Ping Yip, Ozlem Yildiz, Malcolm Ward, Linda Greensmith, Caterina Bendotti, Ian Pike & Andrea Malaspina. (2018) Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Molecular Neurodegeneration 13:1.
Crossref
Crossref
Hélène Blasco, Blandine Madji Hounoum, Diane Dufour‐Rainfray, Franck Patin, François Maillot, Stéphane Beltran, Paul H. Gordon, Christian R. Andres & Philippe Corcia. (2015)
Vitamin D is Not a Protective Factor in
ALS
. CNS Neuroscience & Therapeutics 21:8, pages 651-656.
Crossref
Crossref
S. ZoccolellaI. L. SimoneP. LambertiV. SamarelliR. TortelliL. SerlengaG. Logroscino. (2008) Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology 70:3, pages 222-225.
Crossref
Crossref
M. Mannino, E. Cellura, G. Grimaldi, P. Volanti, F. Piccoli & V. La Bella. (2007) Telephone follow-up for patients with amyotrophic lateral sclerosis. European Journal of Neurology 14:1, pages 79-84.
Crossref
Crossref
Jennica MC Winhammar, Dominic B Rowe, Robert D Henderson & Matthew C Kiernan. (2005) Assessment of disease progression in motor neuron disease. The Lancet Neurology 4:4, pages 229-238.
Crossref
Crossref
P. KaufmannG. LevyJ. L.P. ThompsonM. L. DelBeneV. BattistaP. H. GordonL. P. RowlandB. LevinH. Mitsumoto. (2005) The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64:1, pages 38-43.
Crossref
Crossref